Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

GlaxoSmithKline PLC Director's Dealing 2023

Feb 22, 2023

5262_dirs_2023-02-22_a69c2be3-d273-4924-b516-bd6620856561.html

Director's Dealing

Open in viewer

Opens in your device viewer

National Storage Mechanism | Additional information

RNS Number : 7518Q

GSK PLC

22 February 2023

GSK plc (the 'Company')

Transaction notification

1. Details of PDMR/person closely associated with them ('PCA')
a) Name Ms D Conrad
b) Position/status Chief People Officer
c) Initial notification/

amendment
Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary Shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB00BN7SWP63
b) Nature of the transaction Acquisition of Ordinary Shares following the exercise of options granted on 29 November 2019 at the option price of £14.15 per Ordinary Share under the Company's ShareSave Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£14.15 636
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2023-02-17
f) Place of the transaction London Stock Exchange (XLON)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHSEWFIEEDSEEE